BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30723586)

  • 1. Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.
    Rossi C; Gravelle P; Decaup E; Bordenave J; Poupot M; Tosolini M; Franchini DM; Laurent C; Morin R; Lagarde JM; Ysebaert L; Ligat L; Jean C; Savina A; Klein C; Céspedes AM; Perez-Galan P; Fournié JJ; Bezombes C
    Oncoimmunology; 2019; 8(3):1554175. PubMed ID: 30723586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
    Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
    J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z; Freedman MS
    Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.
    Braza MS; Caraux A; Rousset T; Lafaye de Micheaux S; Sicard H; Squiban P; Costes V; Klein B; Rossi JF
    J Immunol; 2010 Jan; 184(1):134-40. PubMed ID: 19949101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Several immune escape patterns in non-Hodgkin's lymphomas.
    Laurent C; Charmpi K; Gravelle P; Tosolini M; Franchet C; Ysebaert L; Brousset P; Bidaut A; Ycart B; Fournié JJ
    Oncoimmunology; 2015 Aug; 4(8):e1026530. PubMed ID: 26405585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.
    Faria C; Gava F; Gravelle P; Valero JG; Dobaño-López C; Van Acker N; Quelen C; Jalowicki G; Morin R; Rossi C; Lagarde JM; Fournié JJ; Ysebaert L; Laurent C; Pérez-Galán P; Bezombes C
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay.
    Seidel UJ; Vogt F; Grosse-Hovest L; Jung G; Handgretinger R; Lang P
    Front Immunol; 2014; 5():618. PubMed ID: 25520723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
    Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
    Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.
    Ferrarini M; Heltai S; Pupa SM; Mernard S; Zocchi R
    J Natl Cancer Inst; 1996 Apr; 88(7):436-41. PubMed ID: 8618235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
    Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
    Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
    Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
    Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
    Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of tumor-infiltrating TCRV
    Tosolini M; Pont F; Poupot M; Vergez F; Nicolau-Travers ML; Vermijlen D; Sarry JE; Dieli F; Fournié JJ
    Oncoimmunology; 2017; 6(3):e1284723. PubMed ID: 28405516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
    García-Muñoz R; López-Díaz-de-Cerio A; Feliu J; Panizo A; Giraldo P; Rodríguez-Calvillo M; Grande C; Pena E; Olave M; Panizo C; Inogés S
    Immunol Res; 2016 Apr; 64(2):548-57. PubMed ID: 26659089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.
    Péricart S; Tosolini M; Gravelle P; Rossi C; Traverse-Glehen A; Amara N; Franchet C; Martin E; Bezombes C; Laurent G; Brousset P; Fournié JJ; Laurent C
    Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30384489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
    Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
    J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.